Drug-induced respiratory disease in patients with hematological diseases

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 5, 2005, Pages 458-481

  Camus, Philippe ^a   Costabel, Ulrich ^b  

^a HÔPITAL DU BOCAGE   (France)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Chemotherapy induced lung; Drug induced pneumonitis; Radiation pneumonitis

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZATHIOPRINE; BETA INTERFERON; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMATINIB; INTERLEUKIN 2; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOMYCIN C; NITROSOUREA DERIVATIVE; PREDNISONE; PROCARBAZINE; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACUTE CHEST SYNDROME; ACUTE RESPIRATORY FAILURE; ADDISON DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANEMIA; ASTHMA; BRONCHOSPASM; CAPILLARITIS; CAPILLARY LEAK SYNDROME; CLINICAL FEATURE; CLUBBING FINGERS; COUGHING; DIFFERENTIAL DIAGNOSIS; DYSPNEA; FIBEROPTIC BRONCHOSCOPY; HEART ARREST; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LOEFFLER PNEUMONIA; LUNG ALVEOLITIS; LUNG ALVEOLUS PROTEINOSIS; LUNG BIOPSY; LUNG EDEMA; LUNG FIBROSIS; LUNG GRANULOMATOSIS; LUNG HEMORRHAGE; LUNG INFECTION; LUNG INFILTRATE; LUNG INJURY; LUNG LAVAGE; LUNG MALFORMATION; LUNG NODULE; LUNG SARCOIDOSIS; LUNG TOXICITY; LUPUS ERYTHEMATOSUS; LYMPHOCYTOSIS; MALAISE; MUSCLE WEAKNESS; OPPORTUNISTIC INFECTION; ORGANIZING PNEUMONIA; PIGMENT DISORDER; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RASH; RECIPIENT; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SECOND CANCER; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; URTICARIA; VEIN OCCLUSION; VENOUS THROMBOEMBOLISM; WHEEZING;

ANTINEOPLASTIC AGENTS; BIOPSY; BRONCHOSCOPY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; RADIOTHERAPY;

EID: 27644593847     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922030     Document Type: Review

References (300)

1. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004;25:53-64
2. Afessa B. Pretransplant pulmonary evaluation of the blood and marrow transplant recipient. Chest 2005;128:8-10
3. Stiff PJ, Unger JM, Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529-539
4. Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. J Clin Oncol 1990;8:1971-1980
5. Rossi HA, Becker PS, Emmons RV, et al. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;31:441-446
6. Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant 2001;7:552-560
7. Engelfriet CP, Reesink HW, Brand A, et al. Transfusion-related acute lung injury (TRALI). Vox Sang 2001;81:269-283
8. Abratt RP, One FR, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med 2004;25:167-177
9. http://www.pneumotox.com: Pneumotox® Web site: 1997. Producers: P Foucher-Ph. Camus: Last update: July, 2005
10. Bruno B, Souillet G, Bertrand Y, Werck-Gallois MC, So Satta A, Bellon G. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004;34:143-147
11. White DA. Drug-induced pulmonary infection. Clin Chest Med 2004;25:179-188
12. Khurshid I, Anderson LC. Non-infectious pulmonary complications after bone marrow transplantation: thoracic complications related to bone marrow transplantation. Postgrad Med J 2002;78:257-262
13. Franquet T, Muller NL, Lee KS, Gimenez A, Flint JD. High-resolution CT and pathologic findings of noninfectious pulmonary complications after hematopoietic stem cell transplantation. AJR Am J Roentgenol 2005;184:629-637
14. Plataki M, Bouros D. Iatrogenic and rare pleural effusion. In: Bouros D, ed. Pleural Disorders. New York: Dekker; 2004:897-913
15. Zisman DA, McCune WJ, Tino G, Lynch JPI. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:243-252
16. Sleijfer S. Bleomycin pneumonitis. Chest 2001;120:617-624
17. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattamaneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990;323:378-382
18. Erasmus JJ, McAdams HP, Rossi SE. Drug-induced lung injury. Semin Roentgenol 2002;37:72-81
19. Erasmus JJ, McAdams HP, Rossi SE. High-resolution CT of drug-induced lung disease. Radiol Clin North Am 2002;40:61-72
20. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002;57:292-299
21. Mulabecirovic A, Gaulhofer P, Auner HW, et al. Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis. Ann Hematol 2004;83:420-422
22. Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004;25:37-46
23. Bolanos-Meade J, Ioffe O, Hey JC, Vogelsang GB, Akpek G. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. Am J Hematol 2005;79:132-135
24. Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. Arthritis Rheum 1997;40:1829-1837
25. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15:373-381
26. Rossi SE, Erasmus JJ, McAdams P, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;5:1245-1259
27. Fuhrman C, Parrot A, Wislez M, et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001;164:1186-1191
28. Marzouk K, Saleh S, Kannass M, Sharma OP. Interferon-induced granulomatous lung disease. Curr Opin Pulm Med 2004;10:435-440
29. Berkani K, Bayle JY, Perol M, Bejui-Thivolet F, Perrot D, Guérin JC. "Spontaneous" resolution of two severe methotrexate-induced pneumonias. Rev Pneumol Clin 2003;59:301-305
30. Fehr T, Jacky E, Bachli EB. Successful reintroduction of methotrexate after acute, pneumonitis in a patient with acute lymphoblastic leukemia. Ann Hematol 2003;82:193-196
31. Oddo M, Liaudet L, Lepori M, Broccard AF, Schauer MD. Relapsing acute respiratory failure induced by minocycline. Chest 2003;123:2146-2148
32. Baptista JP, Casanova PC, Sousa JP, et al. Acute eosinophilic pneumonia associated with acute respiratory distress syndrome: case report. Rev Port Pneumol 2004;10:355-364
33. Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol 1977;128:1-13
34. Egerer G, Witzens M, Spaeth A, et al. Successful treatment of bronchiolitis obliterans organizing pneumonia with low-dose methotrexate in a patient with Hodgkin's disease. Oncology 2001;61:23-27
35. Kalambokis G, Stefanou D, Arkoumani E, Kitsanou M, Bourantas K, Tsianos EV. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur J Haematol 2004;73:67-70
36. Ferriby D, Stojkovic T. Bronchiolitis obliterans with organizing pneumonia during interferon β-1a treatment. Lancet 2001;357:751
37. Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989;64:806-811
38. Gehl HB, Hauptmann S, Sohn M, Bohndorf K. Late pulmonary changes following bleomycin administration in computed tomography: nodular fibrosis mimicking a seminoma metastasis. Radiologe 1992;32:80-82
39. Ben Arush MW, Roguin A, Zamir E, et al. Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer. Pediatr Hematol Oncol 1997;14:381-386
40. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992;19:508-520
41. Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003;98:978-982
42. Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's lymphoma Study Group. J Clin Oncol 2004;22:2424-2429
43. Rubio C, Hill ME, Milan S, O'Brien MER, Cunningham D. Idiopathic pneumonia syndrome after high dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997;75:1044-1048
44. Quigley M, Brada M, Heron C, Horwich A. Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin's lymphoma. Hematol Oncol 1988;6:319-324
45. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi AC. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993;147:1264-1270
46. Colby TV. Surgical pathology of non-neoplastic lung disease. Mod Pathol 2000;13:343-358
47. Huang MS, Colby TV, Goellner JR, Martin WJ. Utility of bronchoalveolar lavage in the diagnosis of drug induced pulmonary toxicity. Acta Cytol 1989;33:533-538
48. Maehara K, Shiraki M, Hara I, Koike S, Matsumiya T. Possible association of drug therapy with pulmonary alveolar proteinosis (PAP) in patients with malignant haematological disorders. Jpn J Pharmacol 1999;79:285P
49. Du EZ, Yung GL, Le DT, Masliah E, Yi ES, Friedman PJ. Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient. J Thorac Imaging 2001;16:307-309
50. Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997;63:1079-1086
51. Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000;6:387-394
52. Shankar G, Cohen DA. Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. Int J Exp Pathol 2001;82:101-113
53. Wong R, Rondon G, Saliba RM, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 2003;31:1157-1163
54. Shapiro CL, Yeap DY, Godleski J, et al. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma: comparative results with three different treatment regimens. Cancer 1991;68:699-705
55. Moormeier JA, Williams SF, Kaminer LS, Garner M, Bitran JD. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst 1990;82:29-34
56. Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000;25:309-313
57. Brice P, Tredaniel J, Monsuez JJ, et al. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Ann Oncol 1991;2(Suppl 2):73-76
58. Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine. Chest 1995;107:482-487
59. Bhalla KS, Wilczynski SW, Abushamaa AM, et al. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000;161:17-25
60. Maher J, Daly PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993;48:92-94
61. Segura A, Yuste A, Cercos A, et al. Pulmonary fibrosis induced by cyclophosphamide. Ann Pharmacother 2001;35:894-897
62. Lindell RM, Hartman TE. Chest imaging in iatrogenic respiratory disease. Clin Chest Med 2004;25:15-24
63. Dai MS, Lee SC, Ho CL, Chen YC, Kao WY, Chao TY. Impact of open lung biopsy for undiagnosed pulmonary infiltrates in patients with hematological malignancies. Am J Hematol 2001;68:87-90
64. Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997;20:1063-1067
65. White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med 2000;161:723-729
66. Richter JE, Hastedt R, Dalton JF, Marshall D, Raymond LW. Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy. Cancer 1979;43:1607-1612
67. White DA, Orenstein M, Godwin TA, Stover DE. Chemotherapy-associated pulmonary toxic reactions during treatment for breast cancer. Arch Intern Med 1984;144:953-956
68. Zappasodi P, Vitulo P, Volpini E, Castagnola C, Nascimbene C, Corso A. Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injury. Ann Hematol 2002;81:347-349
69. Bell MR, Meredith DJ, Gill PG. Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. Aust N Z J Med 1985;15:235-240
70. Lind PA, Marks LB, Jamieson TA, et al. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue. Cancer 2002;94:2821-2829
71. Wolkowicz J, Sturgeon J, Rawji M, Chan CK. Bleomycin-induced pulmonary function abnormalities. Chest 1992;101:97-101
72. Tucker AS, Newman AJ, Alvorado C. Pulmonary, pleural and thoracic changes complicating chemotherapy. Radiology 1977;125:805-809
73. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use: two distinct patterns. Am J Respir Crit Care Med 1996;154:1851-1856
74. [No authors listed.] The Hamman-Rich syndrome following treatment of lymphoma with chlorambucil. J La State Med Soc 1975;127:311-315
75. Bedrossian CWM, Miller WC, Luna MA. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J 1979;72:313-318
76. Attar EC, Ervin T, Janicek M, Deykin A, Godleski J. Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol 2000;18:697-698
77. Hirschi S, Lange F, Battesti JP, Lebargy F. Pulmonary sarcoid-like granulomatosis associated with Hodgkin's disease and complicated by bleomycin-induced pulmonary nodules. Ann Med Interne (Paris) 1998;149:164-166
78. Kornacker M, Kraemer A, Leo E, Ho AD. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases. Ann Hematol 2002;81:103-105
79. Vandenplas O, Hanston P, Dive A, Mahieu P. Fulminant pulmonary edema following intravenous administration of radiographic media. Acta Clin Belg 1990;45:334-339
80. Vaylet F, Plotton C, Algayres JP, Verkindre C, L'Her P. Oedème aigu du poumon après vinorelbine. Presse Med 1996;25:1259-1260
81. Reed CR, Glauser FL. Drug-induced non cardiogenic pulmonary edema. Chest 1991;100:1120-1124
82. Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 2001;6:153-161
83. Briasoulis E, Froudarakis M, Milionis H, Peponis I, Constantopoulos S, Pavlidis N. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 2000;67:680-683
84. Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med 2004;25:133-140
85. Corso S, Vukelja SJ, Wiener D, Baker WJ. Diffuse alveolar hemorrhage following autologous bone marrow infusion. Bone Marrow Transplant 1993;12:301-303
86. Srivastava A, Gottlieb D, Bradstock KF. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:863-867
87. Glasier CM, Siegel MJ. Multiple pulmonary nodules: unusual manifestation of bleomycin toxicity. AJR Am J Roentgenol 1981;137:155-156
88. Franchi F, Seminara P, Gualdi GF. Lung pseudometastases due to vinblastine toxicity. Klin Wochenschr 1984;62:1047-1048
89. Scharstein R, Johnson JF, Cook BA, Stephenson SR. Bleomycin nodules mimicking metastatic osteogenic sarcoma. Am J Pediatr Hematol Oncol 1987;9:219-221
90. Garg S, Garg MS, Basmaji N. Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature. Am J Hematol 2002;70:241-245
91. Gulbahce HE, Manivel JC, Jessurun J. Pulmonary cytolytic thrombi: a previously unrecognized complication of bone marrow transplantation. Am J Surg Pathol 2000;24:1147-1152
92. Gulbahce HE, Pambuccian SE, Jessurun J, et al. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J Clin Pathol 2004;121:205-210
93. White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer 1987;59:1582-1585
94. Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993;11:1080-1084
95. Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J 1996;60:185-188
96. Urban C, Nirenberg A, Caparros B, Anac S, Cacavio A, Rosen G. Chemical pleuritis as the cause of acute chest pain following high-dose methotrexate treatment. Cancer 1983;51:34-37
97. Brandt RR, Dunn WF, Dry SJ. Dextran 70 embolization: another cause of pulmonary hemorrhage, coagulopathy, and rhabdomyolysis. Chest 1993;104:631-633
98. Rubin RL. Drug-induced lupus. Toxicology 2005;209:135-147
99. Rivera MP, Kris MG, Gralla RJ, White DA. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Am J Clin Oncol 1995;18:245-250
100. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18:465-471
101. Benekli M, Anderson B, Wending D, Bernstein S, Czuczman M, McCarthy P. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplant 2000;25:1299-1301
102. Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin 2001;17:483-502
103. Ferrucci PF, Martinoni A, Cocorocchio E. Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Tranplant 2002;25:173-177
104. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy. Cancer 1979;43:2223-2226
105. Manthorpe R, Svensson O. Cardiomyopathy following intravenous cyclophosphamide therapy in a patient with Wegener's granulomatosis. Clin Exp Rheumatol 1996;14:702-703
106. Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med 2005;352:2456-2457
107. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114:664-666
108. Vincent L, Lamrini R, Pommier P, Martel I, Helfre S, Carrie C. Arrêt cardiaque et vinorelbine? A propos d'un cas et revue de la littérature. Rev Pneumol Clin 1997;53:360-361
109. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005;32:S71-S80
110. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42:743-749
111. Camus P. Drug-induced pleural disease. In: Bouros D, ed. Pleural Disorders. York: Dekker; 2004:317-352
112. Hamada K, Nagai S, Kitaichi M, et al. Cyclophosphamide-induced late-onset lung disease. Intern Med 2003;42:82-87
113. Jensen BV, Carlsen NLT, Groth S, Nissen NI. Late effects on pulmonary function of mantle-field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease. Eur J Haematol 1990;44:165-171
114. Fanfulla F, Locatelli F, Zoia MC, et al. Pulmonary complications and respiratory function changes after bone marrow transplantation in children. Eur Respir J 1997;10:2301-2306
115. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997;8:115-118
116. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87:1530-1537
117. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192
118. Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003;159:161-173
119. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001;19:1610-1618
120. Zablotska LB, Angevine AH, Neugut AI. Therapy-induced thoracic malignancies. Clin Chest Med 2004;25:217-224
121. Tolar J, Coad JE, Ramsay NKC, Peters C, Davies SM. Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation. Bone Marrow Transplant 2001;28:808-810
122. Wright DG, Robichaud KJ, Pizzo PA, Deiseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981;304:1185-1189
123. Arning M, Heer-Sonderhoff AH, Wehmeir A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995;14:41-43
124. Garnacho-Montero J, Ortiz-Leyba C, Garcia-Garmenda JL, Jiminez-Jiminez FJ. Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate. Clin Infect Dis 1998;26:1016
125. Spitzer TR, Creger RJ, Fox RM, Lazarus HM. Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever. Pharmatherapeutica 1989;5:305-311
126. Lowery MM, Greenberger PA. Amphotericin-induced stridor: a review of stridor, amphotericin preparations, and their immunoregulatory effects. Ann Allergy Asthma Immunol 2003;91:460-466
127. Collazos J, Martinez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management. Clin Infect Dis 2001;33:E75-E82
128. Maillard N, Foucher P, Caillot D, Durand C, Sgro C, Camus P. Transient pulmonary infiltrates during treatment with anti-thymocyte globulin. Respiration 1999;66:279-282
129. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia, I: Clinical results. Blood 1990;76:1704-1709
130. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-296
131. Nicolls MR, Terada LS, Tuder RM, Priniville SA, Schwarz MI. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998;158:1302-1305
132. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18:2620-2625
133. Davis BA, Cervi P, Amin Z, Moshi G, Shaw P, Porter J. Retinoic acid syndrome: pulmonary computed tomography (CT) findings. Leuk Lymphoma 1996;23:113-117
134. Maloisel F, Petit T, Kessler R, Oberling F. Cytologic examination of broncho-alveolar fluid during the retinoic acid syndrome. Eur J Haematol 1996;56:319-320
135. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995;9:774-778
136. Goldschmidt N, Gural A, BenYehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia. Leuk Lymphoma 2003;44:1433-1437
137. Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981;8:111-125
138. Smith AC. The pulmonary toxicity of nitrosoureas 1989;41:443-460
139. Massin F, Coudert B, Foucher P, et al. Nitrosourea-induced pneumonitis. Rev Mal Respir 1992;9:575-582
140. Aronin PA, Mahaley MSJ, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med 1980;303:183-188
141. Tucci E, Verdiani P, Di Carlo S, Sforza V. Lomustine (CCNU)-induced pulmonary fibrosis. Tumori 1986;72:95-98
142. Mitsudo SM, Greenwald ES, Banerji B, Koss LG. BCNU (1 3-bis-(2-chloroethyl)-1-nitrosourea) lung: drug-induced pulmonary changes. Cancer 1984;54:751-755
143. Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest 2004;126:1007
144. Ishizuka M, Takayama H, Takeuchi T, Umezawa H. Activity and toxicity of bleomycin. J Antibiot (Tokyo) 1967;20:15-24
145. Balikian JP, Jochelson MS, Bauer KA, et al. Pulmonary complications of chemotherapy regimens containing bleomycin. AJR Am J Roentgenol 1982;139:455-461
146. Trump DL, Bartel E, Pozniak M. Nodular pneumonitis after chemotherapy for germ cell tumors. Ann Intern Med 1988;109:431-432
147. Iacovino JR, Leitner J, Abbas AK, Lokich JJ, Snider GL. Fatal pulmonary reaction from low doses of bleomycin: an idiosyncratic tissue response. JAMA 1976;235:1253-1255
148. Bechard DE, Fairman RP, DeBlois GG, Via CT. Fatal pulmonary fibrosis from low-dose bleomycin therapy. South Med J 1987;80:646-649
149. Einhorn L, Krause M, Hornbarck N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 1976;37:2414-2416
150. Krous HF, Hamlin WB. Pulmonary toxicity due to bleomycin: report of a case. Arch Pathol 1973;95:407-410
151. Toledo CH, Ross WE, Hood CI, Block ER. Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep 1982;66:359-362
152. White DA, Stover DE. Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids. Chest 1984;86:723-728
153. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998;78:1061-1066
154. Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Saf 2003;2:587-596
155. Bargon G. Drug-induced changes in the lungs. Rontgenblatter 1984;37:261-265
156. Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin related lung damage: CT evidence. Radiology 1985;156:155-158
157. Kuhlman JE. The role of chest computed tomography in the diagnosis of drug-related reactions. J Thorac Imaging 1991;6:52-61
158. Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA. Drug-induced pulmonary fibrosis. Saudi Med J 2004;25:700-706
159. Bellamy EA, Nicholas D, Husband JE. Quantitative assessment of lung damage due to bleomycin using computed tomography. Br J Radiol 1987;60:1205-1209
160. Mills P, Husband J. Computed tomography of pulmonary bleomycin toxicity. Semin Ultrasound CT MR 1990;11:417-422
161. Rimmer MJ, Dixon AK, Flower CDR, Sikora K. Bleomycin lung: computed tomographic observations. Br J Radiol 1985;58:1041-1045
162. White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax 1987;42:551-552
163. Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia: relation to bleomycin. Chest 1985;88:103-106
164. O'Neill TJ, Kardinal CG, Tierney LM. Reversible interstitial pneumonitis associated with low-dose bleomycin. Chest 1975;68:265-267
165. Lewis BM, Izbicki R. Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading. JAMA 1980;243:347-351
166. Schaaf W, Vogel H, Kresuer E, Demandt M. Postoperative ARDS as a possible consequence of bleomycin therapy performed 7 years ago: a case study. Anästhesiol Intensivmed 2003;44:436-440
167. Kopko PM, Popovsky MA. Pulmonary injury from transfusion-related acute lung injury. Clin Chest Med 2004;25:105-113
168. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury. Report of a clinical look-back investigation. JAMA 2002;287:1968-1971
169. Popovsky MA. Transfusion and lung injury. Transfus Clin Biol 2001;8:272-277
170. Gajic O, Moore SB. Transfusion-related acute lung injury. Mayo Clin Proc 2005;80:766-770
171. Carilli AD, Ramamurthy MV, Chang Y-S, Shin D, Sehti V. Noncardiogenic pulmonary edema following blood transfusion. Chest 1978;74:310-312
172. Popovsky MA. Transfusion and the lung: circulatory overload and acute lung injury. Vox Sang 2004;87:62-65
173. Dubois M, Lotze MT, Diamond WJ, Kim YD, Flye MW, MacNamara TE. Pulmonary shunting during leukoagglutinin-induced noncardiac pulmonary edema. JAMA 1980;244:2186-2189
174. Yost CS, Matthay MA, Gropper MA. Etiology of acute pulmonary edema during liver transplantation. Chest 2001;119:219-223
175. Levy GJ, Shabot MM, Hart ME, Mya WW, Goldfinger D. Tranfusion-associated noncardiogenic pulmonary edema: report of a case and a warning regarding treatment. Transfusion 1986;26:278-281
176. Massin F, Fur A, Reybet-Degat O, Camus P, Jeannin L. Busulfan-induced pneumonitis. Rev Mal Respir 1987;4:3-10
177. Nelson BM, Andrews GA. Breast cancer and cytologic dysplasia in many organs after Busulfan. Am J Clin Pathol 1964;42:37-44
178. [No authors listed.] Case records of the Massachusetts General Hospital: case 25-1997. N Engl J Med 1997;337:480-489
179. Kirschner RH, Esterly JR. Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia. Cancer 1971;27:1074-1080
180. Aymard JP, Gyger M, Lavallee R, Legresley LP, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia: a peculiar pathologic aspect of busulfan lung? Cancer 1984;53:954-956
181. Littler WA, Ogilvie C. Lung function in patients receiving busulphan. Br Med J 1970;ii:530-532
182. Giles FJ, Smith MP, Goldstone AH. Chlorambucil lung toxicity. Acta Haematol 1990;83:156-158
183. Mohr M, Kingreen D, Rühl H, Huhn D. Interstitial lung disease: an underdiagnosed side-effect of chlorambucil? Ann Hematol 1993;67:305-307
184. Khong HT, McCarthy J. Chlorambucil-induced pulmonary disease: a case report and review of the literature. Ann Hematol 1998;77:85-87
185. Ruiz-Argüelles GJ, Arizpe-Bravo D, Sanchez-Sosa S, Rojas-Ortega S, Moreno-Ford V, Ruiz-Argüelles A. Fatal G-CSF-induced pulmonary toxicity. Am J Hematol 1999;60:82-83
186. Lei KIK, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for agressive non-Hodgkin's lymphoma. Br J Cancer 1994;70:1009-1013
187. Yokose N, Ogata K, Tamura H, et al. Pulmonary toxicity after granulocyte colony stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. Br J Cancer 1998;77:2286-2290
188. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997;111:657-660
189. Gatti E, Scagliotti GV, Ferrari G, et al. Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor. Eur Respir J 1995;8:1566-1571
190. Philippe B, Couderc LJ, Balloul-Delclaux E, Janvier M, Caubarrère I. Pulmonary toxicity of chemotherapy and GM-CSF. Respir Med 1994;88:715
191. Sorhage F, Stover DE, Mortazavi A. Unusual etiology of cough in a woman with asthma. Chest 1996;110:852-854
192. Taillé C, Fartoukh M, Houël R, Kobeiter H, Rémy P, Lemaire F. Spontaneous hemomediastinum complicating steroid-induced mediastinal lipomatosis. Chest 2001;120:311-313
193. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:1958-1964
194. Similowski T, Strauss C. Iatrogenic-induced dysfunction of the neuromuscular respiratory system. Clin Chest Med 2004;25:155-166
195. Kilpiö K, Hannuksela M. Corticosteroid allergy in asthma. Allergy 2003;58:1131-1135
196. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-1838
197. Wolley J, Collett J, Goldstein D. Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen. Aust NZ J Med 1997;27:605-606
198. Cuguillière A, Bérard H, N'Guyen G. Pneumopathie interstitielle liée au cyclophosphamide. Rev Pneumol Clin 1999;55:100-104
199. Burke DA, Stoddart JC, Ward MK, Simpson CGB. Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide. Br Med J 1982;285:696
200. Abdel Karim FW, Ayash RE, Allam C, Salem PA. Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. Oncology 1983;40:174-176
201. Topilow AA, Rothenberg SP, Cottrell TS. Interstitial pneumonia after prolonged treatment with cyclophosphamide. Am Rev Respir Dis 1973;108:114-117
202. Alvarado CS, Boat TF, Newman AJ. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J Pediatr 1978;92:443-446
203. Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 1997;25:215-218
204. [No authors listed.] Case records of the Massachusetts General Hospital: case 35-1984. N Engl J Med 1984;311:585-593
205. Haupt HM, Hutchins GM, Moore GW. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukaemia. Am J Med 1981;70:256-261
206. Jehn U, Göldel N, Rienmüller R, Wilmanns W. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Med Oncol Tumor Pharmacother 1988;5:41-47
207. Shearer P, Katz J, Bozeman P, et al. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia. Cancer 1994;74:1953-1958
208. Andersson BS, Luna BS, Yee C, Hui KK, Keating MJ, McCreadie KB. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer 1990;65:1079-1084
209. Tenenbein M, Adamson IYR. Desferrioxamine and pulmonary injury. Lancet 1992;340:428-429
210. Freedman MH, Grisaru D, Olivieri N, McLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990;144:565-569
211. Miller KB, Rosenwasser LJ, Besserte JAM, Beer DJ, Rocklin RE. Rapid desensitization for desferrioxamine anaphylactic reaction. Lancet 1981;1:1059
212. Fassas A, Gojo I, Rapoport A, et al. Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy. Bone Marrow Transplant 2001;28:399-403
213. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996;14:514-519
214. Cervantes F, Salgado C, Montserrat E, Rozman C. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis. Lancet 1990;336:1130
215. Helman DLJ, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 2002;122:785-790
216. Trojan A, Meier R, Licht A, Taverna C. Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma. Ann Hematol 2002;81:535-537
217. Ales NC, Helman DL, Shorr AF, Byrd JC. Fludarabine associated pulmonary toxicity in chronic in lymphoproliferative disoders: a case series. Blood 2000;96:756a-757a
218. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-291
219. Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85-91
220. Maniwa K, Tanaka E, Inoue T, et al. An autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med 2003;42:1022-1025
221. Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998;11:504-506
222. Sauer-Heilborn A, Kath R, Schneider CP, Hoeffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999;125:637-640
223. Desramé J, Duvic C, Bredin C, et al. Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature. Rev Med Interne 2005;26:179-188
224. Schwonzen M, Spangenberger H, Spengler M. Hydroxyurea-induced pneumonitis. Med Klin (Munich) 2003;98:394-397
225. Antoniou KM, Ferdoutsis E, Bouros D. Interferons and their application in the diseases of the lung. Chest 2003;123:209-216
226. Ramos-Casals M, Mana J, Nardi N, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005;84:69-80
227. Ishizaki T, Sasaki F, Ameshima S, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 1996;9:2691-2696
228. Moriya K, Yasuda K, Koike K, et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 1994;29:514-517
229. Anderson P, Höglund M, Rödjer S. Pulmonary side effects of interferon-α therapy in patients with hematological malignancies. Am J Hematol 2003;73:54-58
230. Kamisako T, Adachi Y, Chihara J, Yamamoto T. Interstitial pneumonitis and interferon-alfa. BMJ 1993;306:896
231. Hoffman SD, Hammadeh R, Shah N. Eosinophilic pneumonitis secondary to pegylated interferon alpha-2b and/or ribavirin. Am J Gastroenterol 2003;98:S152
232. Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994;106:612-613
233. Kumar KS, Russo MW, Borczuk AC. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-2440
234. Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-2440
235. Pileire G, Leclerc P, Hermant P, Meeus E, Camus P. Toux chronique isolée pendant un traitement par interféron. Presse Med 1999;28:913
236. Krasnowska M, Malolepszy J, Liebhart E. Interferon as a bronchospastic factor in patients with bronchial asthma. Pneumonol Alergol Pol 1992;60:22-25
237. Takeda A, Ikegame K, Kimura Y, Ogawa H, Kanazawa S, Nakamura H. Pleural effusion during interferon treatment for chronic hepatitis C. Hepatogastroenterology 2000;47:1431-1435
238. Fruehauf S, Steiger S, Topaly J, Ho AD. Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 2001;80:308-310
239. Price EJ, Venables PJ. Drug-induced lupus. Drug Saf 1995;12:283-290
240. Shaw EG, Deming RL, Creagan ET, et al. Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995;31:827-831
241. Honoré I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003;167:953-957
242. Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002;20:4271-4272
243. Yokoyama T, Miyazawa K, Kurakawa E, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-646
244. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-1579
245. Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinib-associated pulmonary alveolar proteinosis. Am J Med 2003;115:674
246. Taetle R, Dickman PS, Feldman PS. Pulmonary histopathologic changes associated with melphalan therapy. Cancer 1978;42:1239-1245
247. Mufti GJ, Hamblin TJ, Gordon J. Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma. Acta Haematol 1983;69:140-141
248. Lioté H, Gauthier JF, Prier A, Gauthier-Rahman S, Kaplan G, Akoun G. Acute, reversible, interstitial pneumopathy induced by melphalan. Rev Mal Respir 1989;6:461-464
249. Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2000;26:1107-1109
250. Major PP, Laurin S, Bettez P. Pulmonary fibrosis following therapy with melphalan: report of two cases. Can Med Assoc J 1980;123:197-202
251. Clarysse AM, Cathey WJ, Cartwright GE, Wintrobe MM. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA 1969;209:1861-1864
252. Massin F, Coudert B, Marot JP, Foucher P, Camus P, Jeannin L. Methotrexate pneumonitis. Rev Mal Respir 1990;7:5-15
253. Kremer JM, Joong KL. The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-831
254. van der Veen MJ, Dekker JJ, Dinant HJ, Van Soesbergen RM, Bijlsma JWJ. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995;22:1766-1768
255. Renaudier P, Chabot F, Ferry R, et al. Pneumopathies du méthotrexate survenant dans le cadre du traitement des lymphomes non hodkiniens par le protocole m-BACOD. Bull Cancer 1995;82:149-154
256. Pourel J, Guillemin F, Fener P, Webanck L, Bene M-C, Delorme N. Delayed methotrexate pneumonitis in rheumatoid arthritis. J Rheumatol 1991;18:303-304
257. Everts CS, Wescott JL, Bragg DG. Methotrexate therapy and pulmonary disease. Radiology 1973;107:539-543
258. Akoun GM, Mayaud CM, Touboul JL, Denis MF, Milleron BJ, Perrot BJ. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease. Thorax 1987;42:652-655
259. White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18-21
260. Imokawa S, Sato A, Hayakawa H, Toyoshima M, Taniguchi M, Chida K. Possible involvement of an environmental agent in the development of acute eosinophilic pneumonia. Ann Allergy Asthma Immunol 1996;76:419-422
261. Logan PM, Primack SL, Staples C, Miller RR, Müller NL. Acute lung disease in the immunocompromised host: diagnostic accuracy of the chest radiograph. Chest 1995;108:1283-1287
262. 4 cell count may predict this complication. Respir Med 1993;87:153-155
263. Dai MS, Ho CL, Chen YC, Kao WY, Chao TY. Acute respiratory distress syndrome following intrathecal methotrexate administration: a case report and review of literature. Ann Hematol 2000;79:696-699
264. Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross WL. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 1996;15:277-282
265. Newman ED, Harrington TM. Fatal methotrexate pneumonitis in rheumatoid arthritis. Arthritis Rheum 1988;31:1585-1586
266. Cottin V, Tébib J, Massonnet B, Souquet PJ, Bernard J-P. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996;109:933-938
267. Mahmood T, Mudad R. Pulmonary toxicity secondary to procarbazine. Am J Clin Oncol 2002;25:187-188
268. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-614
269. Jones SE, Moore M, Blank N, Castellino RA. Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer 1972;29:498-500
270. Ecker MD, Jay B, Keohane MF. Procarbazine lung. AJR Am J Roentgenol 1978;131:527-528
271. Horton LWL, Chappell AG, Powell DEB. Diffuse interstitial pulmonary fibrosis complicating Hodgkin's disease. Br J Dis Chest 1977;71:44-48
272. Rosenow EC. Chemotherapeutic drug-induced pulmonary disease. Respir Med 1980;2:89-96
273. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999;354:1698-1699
274. Zerga M, Cerchetti L, Cicco J, Constantini P, De Riz M. Desquamative alveolitis: an unusual complication of treatment with Mabthera. Blood 1999;94:271
275. Mangel J, Buckstein R, Imrie K, et al. Pulmonary complications after autologous transplantation and immunotherapy with rituximab in patients with follicular lymphoma [abstract]. Blood 2000;96:383a
276. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-2691
277. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leukemia Lymphoma 2004;45:2321-2325
278. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004;79:949-953
279. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104
280. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005;81:169-170
281. Speirs AL. Thalidomide and congenital abnormalities. Lancet 1962;1:303-305
282. Carrion Valero FC. Lung toxicity due to thalidomide. Arch Bronconeumol 2003;39:286
283. Diaz Garcia B, de Pablo Gafas A, Ferreiro Alvarez MJ. Lung toxicity due to thalidomide. Arch Bronconeumol 2003;39:240
284. Onozawa M, Hashino S, Sogabe S, et al. Thalidomide-induced interstitial pneumonitis. J Clin Oncol 2005;23:2425-2426
285. Iguchi T, Sakoda M, Chen CK, et al. Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma. Rinsho Ketsueki 2004;45:1064-1066
286. Younis TH, Alam A, Paplham P, Spangenthal E, McCarthy P. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol 2003;121:191-192
287. Bennett CL, Schumock GT, Desai AA, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002;113:603-606
288. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003;121:101-103
289. Warren S, Spencer J. Radiation reactions in the lung. AJR Am J Roentgenol 1940;43:682-701
290. Libshitz HI, Southard ME. Complications of radiation therapy: The thorax. Semin Roentgenol 1974;9:41-49
291. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977;86:81-92
292. Pagani JJ, Libshitz HI. CT manifestations of radiation-induced change in chest tissue. J Comput Assist Tomogr 1982;6:243-248
293. Davis SD, Yankelevitz DF, Henschke CI. Radiation effects on the lung: clinical features, pathology, and imaging findings. AJR Am J Roentgenol 1992;159:1157-1164
294. Movsas B, Raffin TA, Epstein AH, Link CJ. Pulmonary radiation injury. Chest 1997;111:1061-1076
295. Logan PM. Thoracic manifestations of external beam radiotherapy. AJR Am J Roentgenol 1998;171:569-577
296. Gibson PG, Bryant DH, Morgan GW, et al. Radiation-induced pneumonitis: a hypersensitivity pneumonitis? Ann Intern Med 1988;109:288-291
297. Jochelson MS, Tarbell NJ, Weinstein HJ. Unusual thoracic radiographic findings in children treated for Hodgkin's disease. J Clin Oncol 1986;4:874-882
298. Goldman AL, Enquist R. Hyperacute radiation pneumonitis. Chest 1975;67:613-615
299. Loyer E, Fuller L, Libshitz HI, Palmer JL. Radiographic appearance of the chest following therapy for Hodgkin disease. Eur J Radiol 2000;35:136-148
300. Crestanello JA, McGregor CGA, Danielson GK, et al. Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy. Ann Thorac Surg 2004;78:826-831